JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M400701200 on April 12, 2004

J. Biol. Chem., Vol. 279, Issue 24, 25307-25312, June 11, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/24/25307    most recent
M400701200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, Y. G.
Right arrow Articles by Lee, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, Y. G.
Right arrow Articles by Lee, B. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Human Mannose-binding Lectin and L-Ficolin Function as Specific Pattern Recognition Proteins in the Lectin Activation Pathway of Complement*

Young Gerl Ma{ddagger}, Mi Yhang Cho{ddagger}, Mingyi Zhao{ddagger}, Ji Won Park{ddagger}, Misao Matsushita§, Teizo Fujita¶, and Bok Luel Lee{ddagger}||

From the {ddagger}College of Pharmacy, Pusan National University, Jangjeon Dong, Kumjeong Ku, Busan 609-735, Korea, §Institute of Glycotechnology and Department of Applied Biochemistry, Tokai University, 1117-Kitakaname, Hiratsuka 259-1292, Japan, Department of Biochemistry, Fukushima Medical University School of Medicine, 1-Hikarigao-ka, and CREST, Japan Science and Technology Agency, Fukushima 960-1295, Japan

Received for publication, January 21, 2004 , and in revised form, March 27, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The innate immune response in vertebrates and invertebrates requires the presence of pattern recognition receptors or proteins that recognize microbial cell components including lipopolysaccharide, bacterial peptidoglycan (PGN), and fungal 1,3-{beta}-D-glucan. We reported previously that PGN and 1,3-{beta}-D-glucan recognition proteins from insect hemolymph were able to induce the activation of the prophenoloxidase-activating system, one of the major invertebrate innate immune reactions. The goal of this study was to characterize the biochemical properties and effects of the human counterparts of these molecules. Soluble pattern recognition proteins were purified from human serum and identified as human mannose-binding lectin (MBL) and L-ficolin. The use of specific microbial cell component-coupled columns demonstrated that MBL and L-ficolin bind to PGN and 1,3-{beta}-D-glucan, respectively. Purified MBL and L-ficolin were associated with MBL-associated serine proteases-1 and -2 (MASPs) and small MBL-associated protein as determined by Western blot analysis. Finally, the binding of purified MBL/MASP and L-ficolin/MASP complexes to PGN and 1,3-{beta}-D-glucan, respectively, resulted in the activation of the lectin-complement pathway. These results indicate that human PGN and 1,3-{beta}-D-glucan recognition proteins function as complement-activating lectins.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Innate immune responses in animals are mediated by specific pattern recognition receptors or proteins that recognize microbe-specific pathogen-associated molecular pattern molecules such as lipopolysaccharide, peptidoglycan (PGN),1 lipoteichoic acid, mannan, and 1,3-{beta}-D-glucan (1–4). This process also occurs in mammals where secreted pattern recognition proteins such as mannose-binding lectin (MBL) and ficolins (L-ficolin and H-ficolin) bind to microbial cells. In human plasma, MBL and ficolins are associated with three types of serine protease termed MBL-associated serine protease (MASP), MASP-1, MASP-2, and MASP-3, and a truncated form of MASP-2 called small MBL-associated protein (sMAP). The complexes promote the elimination of microbes through activation of phagocytosis or the lectin pathway of the complement system (5, 6). Further, pattern recognition receptors expressed on the cell surface, including the family of Toll-like receptors, can activate signaling pathways that induce antimicrobial effectors responses and inflammation upon recognition of different pathogen-associated molecular pattern molecules (1–4). Also, Toll-like receptors expressed on specific antigen-presenting cells play a critical role in the initiation of adaptive immune responses (3, 4).

PGN is a key component of the bacterial cell wall. It is composed of polymeric sugar chains consisting of alternating 1,4-{beta}-linked N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid residues that are cross-linked with shorts peptides (7). Recent studies have demonstrated that PGN activates host cells through the membrane-associated pattern recognition receptors such as Toll-like receptor-2 (8–9) and CD14 (10) and induces the expression of several genes in human monocytes (11). Other investigators have reported (12) that PGN-induced tumor necrosis factor-{alpha} expression is directly mediated via the several transcription factors, which suggests that PGN activates the innate immune system of the host and induces the release of inflammatory molecules.

The cloning of genes encoding vertebrate PGN recognition proteins (PGRPs) demonstrated that there is a high degree of sequence conservation between insects and mammalian species (13–16), indicating that these genes play an important role in the innate immune response. In insects, the recognition of PGN (13, 14) and 1,3-{beta}-D-glucan (17) by PGRPs results in the activation of the prophenoloxidase (pro-PO) activating system, a major humoral defense reaction in arthropods. Moreover, mammalian PGRPs have been shown to possess N-acetylmuramoyl-L-alanine amidase activity (18, 19) and mediate inhibition of bacterial growth (20). Even though several biological functions of PGRPs have been determined, the specific ligands of soluble PGRPs have not been clarified in detail. Further, Girardin et al. (21) report that a novel intracellular PGN recognition protein, Nod-1, detected a unique tripeptide motif found in Gram-negative bacterial PGN and subsequently induced the activation of the NF-kB pathway.

{beta}-Glucans, the major components of yeast and fungal cell walls, are {beta}-1,3- and {beta}-1,6-linked polymers of glucose. They can activate the complement and/or cytokine system, stimulate the reticuloendothelial system, induce hematopoiesis, inhibit tumor cell growth, and induce resistance to infections (for review see Refs. 22 and 23). Several different receptors for {beta}-glucans have been identified including the 60- and 180-kDa proteins in human monocytes and U937 cells (24), dectin-1 in leukocytes (25), the macrophage scavenger receptor (26), the leukocyte complement receptor 3 protein (27), and several putative yet uncharacterized receptors (28, 29).

Here, to further characterize human PGN and 1,3-{beta}-D-glucan recognition molecules, we purified two kinds of complement-related proteins from the human serum by using PGN- and 1,3-{beta}-D-glucan-coupled columns and characterizing their biochemical properties. We found that human MBL and L-ficolin function as secreted pattern recognition proteins for PGN and 1,3-{beta}-D-glucan, respectively.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Preparation of Soluble PGN-coupled Sepharose 4B and 1,3-{beta}-D-Glucan-coupled Toyopearl Resin—A PGN-coupled column was prepared as described previously (17). Soluble PGN fragments were prepared from Staphylococcus aureus insoluble PGN (Fluka Chemie, Steinheim, Germany) according to the published method (30). One milligram of the lyophilized soluble PGN was coupled to 0.4 g of CNBr-activated Sepharose 4B (Amersham Biosciences) according to the manufacturer's recommended protocol, and the PGN-coupled Sepharose binding ability was assessed using recombinant Holotrichia diomphalia PGRP-1 (17). Resins with a binding capability of >10 µg of H. diomphalia PGRP-1 per 1-g resin were used for the purification of PGN recognition proteins in human serum. As a control, CNBr-activated Sepharose 4B that had been inactivated with 100 mM Tris-HCl (pH 8.0) was prepared according to the manufacturer's recommended protocol.

A 1,3-{beta}-D-glucan-coupled column was also prepared as described previously (31). 3 ml of 1,3-{beta}-D-glucan (curdlan, Wako Pure Chemicals, Osaka, Japan) stock solution (500 mg of curdlan was dissolved in 15 ml of 1 N NaOH) was added to 20 ml of 0. 2 M K2HPO4, and the pH was adjusted to 8.4 with 6 M HCl. 2.5 g of suction-dried AF-Amino Toyopearl 650 M (Tosho, Tokyo, Japan) was suspended next in 23 ml of the soluble curdlan solution with 1 g of NaCNBH3 and the mixture was incubated at 60 °C overnight. To block any remaining free amino groups, the gels was acetylated by incubation with 8 ml of 0.2 M sodium acetate and 4 ml of acetic anhydride for 30 min on ice followed by the addition of 4 ml of acetic anhydride and another 30 min of incubation at room temperature. Finally, the resin was washed sequentially with 150 ml of 0.1 M NaOH, 150 ml of 1 M Tris-HCl (pH 8.0), and distilled water. Resin without curdlan served as a control. The amount of 1,3-{beta}-D-glucan coupled to the resins was quantified by the sulfuric acid-phenol method (32). Resins that coupled >3 µg of glucose per 1-mg resin were used for purification of human 1,3-{beta}-D-glucan recognition proteins.

Purification of Human PGN Recognition Proteins—Human plasma was obtained from volunteer donors who had provided written informed consent at the Busan Blood Center (Busan, Korea). The study was performed under the approval for research on human subjects obtained from the Pusan National University. A final concentration of 10 mM CaCl2 was added to the plasma sample followed by incubation at 37 °C for 1 h. Resulting fibrin clots were removed using sterilized gauze and discarded. The fibrin-excluded serum (100 ml) was precipitated with 8 g of polyethylene glycol 4000 (Sigma). After centrifugation at 9,000 rpm for 15 min at 4 °C, the precipitates were dissolved in 15 ml of buffer A (50 mM Tris-HCl (pH 7.8), 200 mM NaCl, and 20 mM CaCl2) and then divided into two batches. Each batch then was loaded on a PGN-coupled Sepharose 4B and control-Sepharose 4B columns that had been equilibrated with buffer A. Both columns were washed with buffer A until the absorbance at 280 nm was zero. Bound proteins were eluted from each column using buffer A containing 0.3 M GlcNAc followed by buffer A containing 0.3 M mannose at a flow rate of 0.3 ml/min. The protein profiles in aliquots of eluted fractions were analyzed by SDS-PAGE under reducing conditions, and fractions containing a 30-kDa protein band were pooled. The pooled fractions were passed through a protein A-attached Sepharose CL 4B (Amersham Biosciences) column equilibrated with buffer A, and the flow-through fractions were passed subsequently through an anti-IgM-coupled Sepharose 4B column. The purified 30-kDa protein was separated by SDS-PAGE under reducing conditions and electroblotted onto a polyvinylidene difluoride membrane for determination of the amino-terminal sequence. For internal amino acid sequencing, proteins were separated by 12% SDS-PAGE under reducing conditions. The gels were stained with 0.2% Coomassie Brilliant Blue in 50% methanol and destained with 30% methanol. The 30-kDa protein band was excised and treated with lysylendopeptidase (Wako Pure Chemicals) according to the method described by Wilm et al. (33). The resulting digest was subjected to reverse phase high performance liquid chromatography (Gilson, WI) using a C18 high performance liquid chromatography column (Tosho). High performance liquid chromatography was performed with a linear gradient of 0–80% acetonitrile in 0.1% trifluoroacetic acid for 75 min at a flow rate of 0.3 ml/min, and the prominent peaks were sequenced using an automatic amino acid sequencer (Procise, Applied Biosystems, Foster City, CA).

Purification of 1,3-{beta}-D-Glucan Recognition Proteins—Human serum was precipitated with polyethylene glycol as described above and dissolved in buffer A. Samples then were loaded onto a 1,3-{beta}-D-glucan-coupled Toyopearl column equilibrated with buffer A. The column was washed with buffer A until the absorbance at 280 nm was zero, and bound proteins were sequentially eluted with buffer A containing 0.3 M glucose, 0.3 M mannose, and 0.3 M GlcNAc. Eluted proteins were analyzed by SDS-PAGE under reducing conditions. The fractions most enriched in the 35-kDa band were blotted onto a polyvinylidene difluoride membrane, and the amino-terminal sequence or partial amino acid sequences of this protein were determined as described above.

Immobilization of Soluble PGN Fragments—Carboxyl-enzyme-linked immunosorbent assay 96-well microplates (Sumitomo Bakelite, Tokyo, Japan) were activated with 100 µl of water-soluble carbodiimide (10 µg/ml) in phosphate-buffered saline (pH 5.8) by incubation at 37 °C for 2 h. The wells were washed three times with 300 µl of phosphate-buffered saline, and 100 µl of soluble PGN was added to each well (~3 µg of lyophilized-soluble PGN fragments) followed by incubation at 37 °C for 2 h. The wells then were washed with 300 µl of phosphate-buffered saline containing 0.05% Tween 20 (pH 7.6). Microplates without PGN served as controls.

Immobilization of 1,3-{beta}-D-Glucan—Amino-enzyme-linked immunosorbent assay 96-well microplates coupled with 1,3-{beta}-D-glucan were prepared by adding 200 µl of soluble curdlan solution to each well and incubating the plates at 60 °C for 30 min. 100 µl of a NaBH3CN solution (20 mg of NaBH3CN dissolved in 0.2 M K2HPO4, (pH 9.4)) was added next to each well and incubated at 60 °C for 14 h. Wells were washed three times with distilled water, twice with 100 mM of boric acid (pH 8.2), and another three times with distilled water. 160 µl of 0.4 M sodium acetate and 160 µl of acetic anhydride were added next to each well, and the plates were incubated at 4 °C for 30 min. The supernatant was discarded, and 300 µl of acetic anhydride was added followed by incubation at room temperature for 30 min. The wells were washed three times with distilled water, three times with 0.1 M NaOH, three times with 1 M of Tris-HCl (pH 8.0), and another six times with distilled water.

Antibodies and Immunoblotting—Mouse monoclonal antibody against MASP-1 (1E2) was prepared as described previously (34). Rabbit polyclonal antibody recognizing the amino terminus of MASP-2/sMAP (35, 36) was provided by Dr. I. Terai (Health Sciences University of Hokkaido, Sapporo, Japan). For immunoblotting, protein samples were subjected to SDS-PAGE under non-reducing and reducing conditions and transferred electrophoretically to polyvinylidene difluoride membranes. Membranes were blocked by immersion in TBST (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.02% Tween 20) containing 5% skim milk and 1% horse serum for 12 h. The membranes were then transferred to a solution containing antibodies against MASP-1 (50 µg/ml) or MASP-2 (5 µg/ml) and then incubated at 4 °C for 2 h and then later with horseradish peroxidase-labeled rabbit-goat IgG conjugate as secondary antibody (1:3,000, Amersham Biosciences). The bound antibodies were detected using an ECL Western blotting reagent kit (Amersham Biosciences).

Binding Assays—PGN-and 1,3-{beta}-D-glucan-coupled microplates were blocked with Block-Ace (0.3 ml, Dainippon Pharmaceutical, Osaka, Japan), and the purified human MBL/MASP or L-ficolin/MASP (4 µg of protein/100 µl in TBST) complexes were diluted with TBST containing 10 mM CaCl2 and incubated at 4 °C for 2 h. After washing with TBST, a biotinylated anti-MBL monoclonal antibody (3E7) (37) or a biotinylated anti-L-ficolin-monoclonal antibody (2F5) (38) was added to the wells and the plates were incubated at 37 °C for 1 h. The wells were washed again and then incubated with an avidin-peroxidase complex (Vector Laboratories, Burlingame, CA) at 37 °C for 1 h. The reaction was developed with ABTS (azino-di-(3-methylbenzthiazoline) sulfonic acid, Zymed Laboratories Inc., San Francisco, CA). The amount of the MBL/MASP complexes or L-ficolin/MASP complexes bound to plates was determined by measuring the absorbance at 405 nm (A405).

C4 Activation Assay—The activation of the lectin-complement pathway was determined by the C4 cleavage assay as described by Petersen et al. (39). PGN- and 1, 3-D-{beta}-glucan-coupled microplates were blocked with Block-Ace, and the purified MBL/MASP or ficolin/MASP complexes (8 µg of protein/well) were incubated at 4 °C for 2 h. The wells were washed first with TBST and then with mannitol gelatin veronal buffer (5 mM veronal, 74 mM NaCl, 0.1% gelatin, 2.3% mannitol, 2 mM CaCl2, and 0.5 mM MgCl2 (pH 7.4)). Human C4 (0.3 µg) was added to each well, and the plates were incubated at 37 °C for 1 h. The wells then were washed with TBST, and C4 deposition was detected by incubation with horseradish peroxidase-conjugated polyclonal anti-C4 antibody (horseradish peroxidase-anti-C4) at 37 °C for 1 h followed by development with ABTS. The amount of C4 deposition was determined by measuring the absorbance at 405 nm.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Isolation of Human MBL Using PGN-coupled Sepharose 4B—PGN-coupled Sepharose 4B columns and the control-Sepharose 4B columns were loaded with human serum precipitate. Upon elution with 0.3 M GlcNAc, no differences were observed in the elution profiles of proteins eluted from the two columns as determined by SDS-PAGE analysis (data not shown). However, the elution of the PGN-Sepharose column with 0.3 M GlcNAc followed by 0.3 M mannose yielded a 30-kDa band (Fig. 1A, Band-a). Furthermore, the amino-terminal sequence and two partial amino acid sequences (M-1 and M-2) of Band-a were identical to the sequences of human MBL (Fig. 1B). Human IgG and IgM from the PGN column were removed through the use of the protein A and the anti-IgM column, which yielded a homogenate of MBL (Fig. 1C, lane 5). In all, ~148 µg of human MBL was obtained when 100 ml of human plasma was loaded onto the PGN-coupled column. These results suggest that human MBL recognizes and binds to soluble PGN.



View larger version (37K):
[in this window]
[in a new window]
  		FIG. 1.
A, SDS-PAGE of the mannose elution fractions from the PGN-Sepharose column under reducing conditions. Lane 1, crude human serum; lane 2, flow-through fraction; lanes 3–14, elution fractions with 0.3 M mannose. Arrows indicate the heavy (H) and light (L) chains of IgG and IgM. B, amino-terminal sequence comparison of Band-a with that of human MBL. Two partial amino acid sequences (Met-1 and Met-2) of Band-a are compared with human MBL. C, MBL purification procedure using protein A, anti-IgM column, and SDS-PAGE. Lane 1, crude serum; lane 2, flow-through fraction of the PGN column; lane 3, the pooled fractions of 0.3 M mannose elution from the PGN column; lane 4, the pass-through fraction of lane 3 on the protein A column; lane 5, the pass-through fraction of lane 4 on the anti-IgM column.

 
Isolation of Human L-Ficolin Using 1,3-{beta}-D-Glucan-coupled Toyopearl—Human serum precipitate was loaded on a 1,3-{beta}-D-glucan-coupled Toyopearl column. When the column was eluted with either 0.3 M glucose or 0.3 M mannose, IgG or IgM alone could be isolated (Fig. 2A, lanes 2–5 and 7–10, respectively). When 1,3-{beta}-D-glucan-coupled column was eluted with 0.3 M GlcNAc, a 35-kDa protein was isolated (Band-b, lanes 11–14). The amino-terminal sequence of Band-b was identical to that of human L-ficolin (Fig. 2B). The removal of human IgG and IgM as described above resulted in a homogenate of L-ficolin (Fig. 2C, lane 4). In all, ~75 µg of L-ficolin was obtained when 100 ml of human plasma was loaded onto the 1,3-{beta}-D-glucan-coupled column. Further, L-ficolin did not bind to control-Toyopearl column (Fig. 2D), and MBL was present in the pass-though fraction of the 1,3-{beta}-D-glucan-coupled column (Fig. 2E). These data suggest that L-ficolin recognizes and binds to 1,3-{beta}-D-glucan.



View larger version (53K):
[in this window]
[in a new window]
  		FIG. 2.
Purification of L-ficolin from the 1,3-{beta}-D-glucan column and binding specificity of L-ficolin. A, SDS-PAGE of glucose and mannose and GlcNAc elution fractions from the 1,3-{beta}-D-glucan column under reducing conditions. Lanes 1 and 6, MBL-containing fractions eluted with 0.3 M mannose from the PGN column; lanes 2–5, 0.3 M glucose elution; lanes 7–10, 0.3 M mannose elution; lanes 11–14, 0.3 M GlcNAc elution. B, amino-terminal sequence comparison of Band-b with that of human L-ficolin. C, purification of L-ficolin using protein A and anti-IgM columns. The purification methods are similar to those described in Fig. 1. Lane 1, crude serum; lane 2, pooled L-ficolin-containing fractions (lanes 11–14 in Fig. 2A); lane 3, pass-through fraction from the protein A column; lane 4, pass-through fraction from the anti-IgM column. D, examination of the binding specificity of L-ficolin on the control-Toyopearl column using SDS-PAGE. Lane 1, purified L-ficolin from the 1,3-{beta}-D-glucan column; lane 2, pass-through fraction from the purified L-ficolin on the control-Toyopearl column; lane 3, 0.3 M GlcNAc elution fractions from the control-Toyopearl column. E, Western blot analysis using monoclonal anti-MBL antibody. Lane 1, the purified MBL (0.2 µg); lane 2, crude serum (25 µg); lane 3, polyethylene glycol precipitate of serum (15 µg); lane 4, the pass-through fraction from lane 3 on the 1,3-{beta}-D-glucan column (15 µg); lane 5, the elution fraction using 0.3 M mannose on the 1,3-{beta}-D-glucan column (1 µg).

 
Association of Purified MBL and L-Ficolin with MASPs—To determine whether MBL and L-ficolin associate with MASPs, eluents were subjected to Western blot analysis using anti-MASP-1 and anti-MASP-2/sMAP antibodies. MASP-1, MASP-2, and sMAP were detected along with MBL in the pass-through fractions from the protein A column (Fig. 3, A and B, lane 1) and from the anti-IgM column (Fig. 3, A and B, lane 2) under non-reducing conditions and reducing conditions, respectively. Further, purified L-ficolin from the 1,3-{beta}-D-glucan-column was associated with MASP-1, MASP-2, and sMAP (Fig. 3, C and D).



View larger version (42K):
[in this window]
[in a new window]
  		FIG. 3.
Association of MBL and L-ficolin with MASP-1, MASP-2, and sMAP. A and B, fraction containing MBL of the PGN column was passed through a protein A column (lane 1) and an anti-IgM column (lane 2). Proteins were analyzed by SDS-PAGE under non-reducing (A) and reducing conditions (B). C and D, L-ficolin containing fractions of the 1,3-{beta}-D-glucan column were passed through a protein A and an anti-IgM column. Proteins were analyzed by SDS-PAGE under nonreducing (C) and reducing conditions (D). After SDS-PAGE, immunoblotting was performed as described under "Experimental Procedures." Ab, antibody.

 
Because human MASPs hydrolyze several chromogenic substrates (40), the amidase activity of the purified MBL/MASP and L-ficolin/MASP complexes was assessed using t-butyloxycarbonyl-L-leucyl-L-seryl-L-threonyl-L-arginine 4-methyl-coumaryl-7-amide (Peptide Institute, Osaka, Japan). Specific amidase activity was observed (data not shown), suggesting that the active forms of MASPs are co-purified with MBL and L-ficolin. These data suggest that purified MBL and L-ficolin are associated with MASP-1, MASP-2, and sMAP.

Activation of the Lectin Pathway of Complement—To examine the complement activation capacity of the two purified lectins, we next examined whether the purified MBL/MASP complexes and L-ficolin/MASP complexes can bind to PGN and 1,3-{beta}-D-glucan, respectively. For this experiment, PGN and 1,3-{beta}-D-glucan were chemically coupled with carboxyl- and amino-enzyme-linked immunosorbent assay microplates, respectively. Purified L-ficolin/MASP complexes exhibited stronger binding to 1,3-{beta}-D-glucan-coupled microplates (Fig. 4A, second column) than to PGN-coupled plate (Fig. 4A, first column). In contrast, MBL/MASP complexes showed strong binding to PGN plates (Fig. 4B, first column) but did not bind significantly to 1,3-{beta}-D-glucan-coupled plates (Fig. 4B, second column). These results clearly support that the binding specificities of the MBL and L-ficolin against PGN and 1,3-{beta}-D-glucan, respectively, are consistent with the results of the column chromatographies.



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 4.
Binding of purified L-ficolin/MASP complexes (A) and purified MBL/MASP complexes (B) to the PGN-coupled plate, 1,3-{beta}-D-glucan-coupled plate, and control microplates. Experiments were carried out as described under "Experimental Procedures." Data are expressed as the mean ± S.D. from a measurement made in triplicate.

 
Previous studies demonstrate that MASP-2 cleaves C4 to C4a and C4b when its complexes with MBL and L-ficolin engage complementary carbohydrate ligands on the surface of microorganisms, leading to the covalent linking of C4b to such pathogens (C4 deposition) (39). Using the fixed PGN and 1,3-{beta}-D-glucan plates, we measured the ability of cleaving C4 by the purified MBL and L-ficolin. C4 cleavage and subsequent C4b deposition occurred in PGN plates incubated with MBL/MASP (Fig. 5A, first column) or L-ficolin/MASP complexes (Fig. 5B, first column) as well as with 1,3-{beta}-D-glucan plates incubated with L-ficolin/MASP complexes (Fig. 5C, first column). There was also a low level of C4 cleavage when PGN plates were incubated with L-ficolin/MASP complexes (Fig. 5B, first column), reflecting the weaker binding of L-ficolin/MASP complexes to PGN as demonstrated above. However, this did not occur in 1,3-{beta}-D-glucan plates incubated with MBL/MASP complexes (Fig. 5D, first column). These results suggest that PGN and 1,3-{beta}-D-glucan may stimulate the lectin pathway of the complement via MBL/MASP and L-ficolin/MASP complexes, respectively.



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 5.
Proteolytic activation of C4 by MBL/MASP complexes (A) and L-ficolin/MASP complexes (B) on the PGN-coupled microplates and L-ficolin/MASP complexes (C) and MBL/MASP complexes (D) on the 1,3-{beta}-D-glucan-coupled microplates. Experiments were carried out as described under "Experimental Procedures." Data are expressed as the mean ± S.D. from a measurement made in triplicate.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Recent studies have demonstrated that human MBL and L-ficolin constitute a group of soluble pattern recognition proteins that can stimulate the lectin pathway of the complement following binding to several ligands, such as mannan (41), lipoteichoic acid (42), GlcNAc (38), lipopolysaccharide (43), and several pathogenic microbes including bacteria and fungi (44). However, no biochemical data regarding specific interactions between soluble PGN or 1,3-{beta}-D-glucan and MBL/MASP or L-ficolin/MASP complexes have been reported. In this result, we have shown that L-ficolin/MASP complexes bound to 1,3-{beta}-D-glucan and MBL/MASP complexes bound to S. aureus PGN can induce the activation of complement protein C4.

Our results provide biochemical evidence of the recent observation (45) that MBL/MASP complexes binding to S. aureus cells enhanced complement activation and opsonophagocytosis. Two recent reports (42, 43) demonstrate that MBL/MASP complexes can bind to lipopolysaccharide and that L-ficolin/MASP complexes can bind to lipoteichoic acid, a cell component found in all Gram-positive bacteria. These interactions lead to C4 deposition, suggesting that lipopolysaccharide and lipoteichoic acid can activate the lectin pathway of the complement via MBL and L-ficolin, respectively. The diverse recognition abilities of human MBL and L-ficolin against different pathogen-associated molecular pattern molecules and the co-existence of MBL and L-ficolin in serum are expected to enlarge the spectrum of pathogenic microorganisms that can be recognized and eliminated through the lectin pathway of the complement activation.

Recent data support that the arthropod pro-PO system has similarity with the mammalian lectin pathway of the complement system (46–48). Both the pro-PO activation system and the lectin pathway of the complement are proteolytic cascades comprising pattern recognition proteins, several serine proteases, and their inhibitors and terminate with the zymogen, pro-PO, and the membrane attack complex, respectively (49). In our previous studies, when we tried to purify 1,3-{beta}-D-glucan recognition molecules from insect hemolymph, we obtained insect 1,3-{beta}-D-glucan recognition protein and PGRPs-like proteins. These molecules triggered the activation of insect pro-PO system in association with an unidentified serine protease (17, 31). In this study, MBL and L-ficolin from human serum were shown to act as pattern recognition molecules for PGN and 1,3-{beta}-D-glucan. These molecules were also found to be associated with MASP and sMAP. Among them, MASP-2 could activate the C4 component of the complement. These data provide strong evidence for a highly conserved nature of innate immunity from insects to mammals.

L-Ficolin is shown to have a carbohydrate binding specificity for GlcNAc (38, 50). Because {beta}-glucan has a backbone structure of {beta}-1,3-linked glucoses, the reason why L-ficolin bound to 1.3-{beta}-D-glucan and eluted with GlcNAc remains to be elucidated. In addition, L-ficolin can bind to the PGN column and also to the control-Sepharose (data not shown), indicating that L-ficolin is not a specific PGN recognition protein. Previously, Le et al. (51) reported that L-ficolin could bind to CNBr-activated Sepharose that had been inactivated with Tris and could be eluted from the preparation using GlcNAc. They also postulated that L-ficolin might recognize an amide group (-CO-NH-) or a similar group with an amide linkage of the control-Sepharose (52). However, in this study, a considerable amount of L-ficolin was bound to PGN. Because PGN is composed of sugar chains consisting of alternating GlcNAc and N-acetylmuramic acid, the possibility remains that L-ficolin bound specifically to PGN. This point still is to be clarified.

In conclusion, this study shows that human MBL and L-ficolin specifically recognize soluble PGN and 1,3-{beta}-D-glucan, respectively, and that subsequently these PGN- and 1,3-{beta}-D-glucan-recognizing pattern proteins can induce C4 activation of the complement. In addition, PGN-coupled Sepharose or 1,3-{beta}-D-glucan-coupled Toyopearl may provide a step in an improved purification procedure for human MBL/MASP complexes or ficolin/MASP complexes to study their biological and functional studies.


   FOOTNOTES
 
* This work was supported in part by a research grant from the Korean Research Foundation (KRF-2003-041-C20203), a Korea Food and Drug Administration grant (KFDA-03142-BIO-022) (to B. L. L.), and a Pusan National University Research grant (to B. L. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed. Tel.: 82-51-510-2809; Fax: 82-51-513-6754; E-mail: brlee{at}pusan.ac.kr.

1 The abbreviations used are: PGN, peptidoglycan; MBL, mannose-binding lectin; MASP, MBL-associated serine protease; sMAP, small MBL-associated protein; GlcNAc, N-acetylglucosamine; PGRP, peptidoglycan recognition protein; pro-PO, prophenoloxidase. Back


   ACKNOWLEDGMENTS
 
We thank Dr. I. Terai for providing anti-MASP-2 antibody and Dr. Kenneth Söderhäll for editing the paper.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Medzhitov, R., and Janeway, C. A. (2002) Science 296, 298-300[Abstract/Free Full Text]
  2. Hoffmann, J. A., Kafatos, F. C., Janeway, C. A., and Ezekowitz, R. A. (1999) Science 284, 1313-1318[Abstract/Free Full Text]
  3. Aderem, A., and Ulevitch, R. J. (2000) Nature 406, 782-787[CrossRef][Medline] [Order article via Infotrieve]
  4. Janeway, C. A., and Medzhitov, R. (2002) Annu. Rev. Immunol. 20, 197-216[CrossRef][Medline] [Order article via Infotrieve]
  5. Holmskov, U., Thiel, S., and Jensenius, J. C. (2003) Annu. Rev. Immunol. 21, 547-578[CrossRef][Medline] [Order article via Infotrieve]
  6. Matsushita, M., and Fujita, T. (2001) Immunol. Rev. 180, 78-85[CrossRef][Medline] [Order article via Infotrieve]
  7. Rogers, H. J., Perkins, H. R., and Ward, J. B. (1980) in Microbial Cell Wall and Membranes (Roger, H. J., ed) pp. 190-382, Chapman & Hall, London
  8. Schwandner, R., Dziarski, R., Wesche, H., Rothe, M., and Kirschning, C. J. (1999) J. Biol. Chem. 274, 17406-17409[Abstract/Free Full Text]
  9. Yoshimura, A., Lien, E., Ingalls, R. R., Tuomanen, E., Dziarski, R., and Golenbock, D. (1999) J. Immunol. 163, 1-5[Abstract/Free Full Text]
  10. Weidemann, B., Brade, H., Rietschel, E. T., Dziarski, R., Bazil, V., Kusumoto, S., Flad, H. D., and Ulmer, A. J. (1994) Infect. Immun. 62, 4709-4715[Abstract/Free Full Text]
  11. Wang, Z. M., Liu, C. L., and Dziarski, R. (2000) J. Biol. Chem. 275, 20260-20267[Abstract/Free Full Text]
  12. Xu, Z., Dziarski, R., Wang, Q., Swartz, K., Sakamoto, K. M., and Gupta, D. (2001) J. Immunol. 167, 6975-6981[Abstract/Free Full Text]
  13. Yoshida, H., Kinoshita, K., and Ashida, M. (1996) J. Biol. Chem. 271, 13854-13860[Abstract/Free Full Text]
  14. Kang, D., Liu, G., Lundstrom, A., Gelius, E., and Steiner, H. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 10078-10082[Abstract/Free Full Text]
  15. Ochiai, M., and Ashida, M. (1999) J. Biol. Chem. 274, 11854-11858[Abstract/Free Full Text]
  16. Liu, C., Xu, Z., Gupta, D., and Dziarski, R. (2001) J. Biol. Chem. 276, 34686-34694[Abstract/Free Full Text]
  17. Lee, M. H., Osaki, T., Lee, J. Y., Baek, M. J., Zhang, R., Park, J. W., Kawabata, S. I., Söderhäll, K., and Lee, B. L. (2004) J. Biol. Chem. 279, 3218-3227[Abstract/Free Full Text]
  18. Gelius, E., Persson, C., Karlsson, J., and Steiner, H. (2003) Biochem. Biophys. Res. Commun. 306, 988-999[CrossRef][Medline] [Order article via Infotrieve]
  19. Wang, Z. M., Li, X., Cocklin, R. R., Wang, M., Wang, M., Fukase, K., Inamura, S., Kusumoto, S., Gupta, D., and Dziarski, R. (2003) J. Biol. Chem. 278, 49044-49052[Abstract/Free Full Text]
  20. Liu, C., Gelius, E., Liu, G., Steiner, H., and Dziarski, R. (2000) J. Biol. Chem. 275, 24490-24499[Abstract/Free Full Text]
  21. Girardin, S. E., Boneca, I. G., Carneiro, L. A., Antignac, A., Jehanno, M., Viala, J., Tedin, K., Taha, M. K., Labigne, A., Zahringer, U., Coyle, A. J., DiStefano, P. S., Bertin, J., Sansonetti, P. J., and Philpott, D. J. (2003) Science 300, 1584-1587[Abstract/Free Full Text]
  22. Sakurai, T., Ohno, N., and Yadomae, T. (1994) Biol. Pharm. Bull. 17, 617-622[Medline] [Order article via Infotrieve]
  23. Williams, D. L., Mueller, A., and Browder, I. W. (1996) Clin. Immunother. 5, 392-399
  24. Szabo, T., and BeMiller, J. N. (1995) J. Biol. Chem. 270, 2145-2151[Abstract/Free Full Text]
  25. Brown, G. D., and Gordon, S. (2001) Nature 413, 36-37[Medline] [Order article via Infotrieve]
  26. Rice, P. J., Kelley, J. L., Kogan, G., Ensley, H. E., Kalbfleisch, J. H., Browder, I. W., and Williams, D. L. (2002) J. Leukocyte Biol. 72, 140-146[Abstract/Free Full Text]
  27. Thornton, B. P., Vetvicka, V., Pitman, M., Goldman, R. C., and Ross, G. D. (1996) J. Immunol. 156, 1235-1246[Abstract]
  28. Konopski, Z., Smedsrod, B., Seljelid, R., and Eskeland, T. (1994) Biochim. Biophys. Acta 1221, 61-65[Medline] [Order article via Infotrieve]
  29. Muller, C. D., Bocchini, V., Giaimis, J., Guerrieri, P., Lombard, Y., and Poindron, P. (1994) Res. Immunol. 145, 267-275[CrossRef][Medline] [Order article via Infotrieve]
  30. Rosenthal, R. S., and Dziarski, R (1994) Methods Enzymol. 235, 253-285[Medline] [Order article via Infotrieve]
  31. Zhang, R., Cho, H. Y., Kim, H. S., Ma, Y. G., Osaki, T., Kawabata, S. I., Söderhäll, K., and Lee, B. L. (2003) J. Biol. Chem. 278, 42072-42079[Abstract/Free Full Text]
  32. Rao, P., and Pattabiraman, T. N. (1980) Anal. Biochem. 181, 18-22
  33. Wilm, M., Shevchenko, A., Houthaeve, T., Breit, S., Schweigerer, L., Fotsis, T., and Mann, M. (1996) Nature 379, 466-469[CrossRef][Medline] [Order article via Infotrieve]
  34. Matsushita, M., and Fujita, T. (1992) J. Exp. Med. 176, 1497-1502[Abstract/Free Full Text]
  35. Thiel, S., Vorup-Jensen, T., Stover, C. M., Schwaeble, W., Laursen, S. B., Poulsen, K., Willis, A. C., Eggleton, P., Hansen, S., Holmskov, U., Reid, K. B., and Jensenius, J. C. (1997) Nature 386, 506-510[CrossRef][Medline] [Order article via Infotrieve]
  36. Matsushita, M., Thiel, S., Jensenius, J. C., Terai, I., and Fujita, T. (2000) J. Immunol. 165, 2637-2642[Abstract/Free Full Text]
  37. Terai, I., Kabayashi, K., Fujita, T., and Hagiwara, K. (1993) Biochem. Med. Metabol. Biol. 50, 111-119[CrossRef][Medline] [Order article via Infotrieve]
  38. Matsushita, M., Endo, Y., Taira, S., Sato, Y., Fujita, T., Ichikawa, N., Nakata, M., and Mizuochi, T. (1996) J. Biol. Chem. 271, 2448-2454[Abstract/Free Full Text]
  39. Petersen, S. V., Thiel, S., Jensen, L., Steffensen, R., and Jensenius, J. C. (2001) J. Immunol. Methods 257, 107-116[CrossRef][Medline] [Order article via Infotrieve]
  40. Ambrus, G., Gal, P., Kojima, M., Szilagyi, K., Balczer, J., Antal, J., Graf, L., Laich, A., Moffatt, B. E., Schwaeble, W., Sim, R. B., and Zavodszky, P. (2003) J. Immunol. 170, 1374-1382[Abstract/Free Full Text]
  41. Ohta, M., Okada, M., Yamashina, I., and Kawasaki, T. (1990) J. Biol. Chem. 265, 1980-1984[Abstract/Free Full Text]
  42. Lynch, N. J., Roscher, S., Hartung, T., Morath, S., Matsushita, M., Maennel, D. N., Kuraya, M., Fujita, T., and Schwaeble, W. J. (2004) J. Immunol. 172, 1198-1202[Abstract/Free Full Text]
  43. Zhao, L., Ohtaki, Y., Yamaguchi, K., Matsushita, M., Fujita, T., Yokochi, T., Takada, H., and Endo, Y. (2002) Blood 100, 3233-3239[Abstract/Free Full Text]
  44. Neth, O., Jack, D. L., Dodds, A. W., Holzel, H., Klein, N. J., and Turner, M. W. (2000) Infect. Immun. 68, 688-693[Abstract/Free Full Text]
  45. Neth. O., Jack, D. L., Johnson, M., Klein, N. J., and Turner, M. W. (2002) J. Immunol. 169, 4430-4436[Abstract/Free Full Text]
  46. Söderhäll, K., and Cerenius, L. (1998) Curr. Opin. Immunol. 10, 23-28[CrossRef][Medline] [Order article via Infotrieve]
  47. Ashida, M., and Brey, P. T. (1998) in Molecular Mechanisms of Immune Responses in Insects (Brey, P. T., and Hultmark, D., eds) pp. 135-172, Chapman & Hall, New York
  48. Gillespie, J., Kanost, M. R., and Trenczek, T. (1997) Annu. Rev. Entomol. 42, 611-643[CrossRef][Medline] [Order article via Infotrieve]
  49. Walport, M. J. (2001) New Engl. J. Med. 344, 1058-1066[Free Full Text]
  50. Matsushita, M., Endo, Y., and Fujita, T. (2000) J. Immunol. 164, 2281-2284[Abstract/Free Full Text]
  51. Le, Y., Tan, S. M., Lee, S. H., Kon, O. L., and Lu, J. (1997) J. Immunol. Methods 204, 43-49[CrossRef][Medline] [Order article via Infotrieve]
  52. Le, Y., Lee, S. H., Kon, O. L., and Lu, J. (1998) FEBS Lett. 425, 367-370[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Infect. Immun.Home page
Y. Aoyagi, E. E. Adderson, C. E. Rubens, J. F. Bohnsack, J. G. Min, M. Matsushita, T. Fujita, Y. Okuwaki, and S. Takahashi
L-Ficolin/Mannose-Binding Lectin-Associated Serine Protease Complexes Bind to Group B Streptococci Primarily through N-Acetylneuraminic Acid of Capsular Polysaccharide and Activate the Complement Pathway
Infect. Immun., January 1, 2008; 76(1): 179 - 188.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Garlatti, L. Martin, E. Gout, J.-B. Reiser, T. Fujita, G. J. Arlaud, N. M. Thielens, and C. Gaboriaud
Structural Basis for Innate Immune Sensing by M-ficolin and Its Control by a pH-dependent Conformational Switch
J. Biol. Chem., December 7, 2007; 282(49): 35814 - 35820.
[Abstract] [Full Text] [PDF]

Home page
 Poult. Sci.Home page
T. C. W. Ploegaert, G. De Vries Reilingh, M. G. B. Nieuwland, A. Lammers, H. F. J. Savelkoul, and H. K. Parmentier
Intratracheally Administered Pathogen-Associated Molecular Patterns Affect Antibody Responses of Poultry
Poult. Sci., August 1, 2007; 86(8): 1667 - 1676.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B.-S. Feng, S.-H. He, P.-Y. Zheng, L. Wu, and P.-C. Yang
Mast Cells Play a Crucial Role in Staphylococcus aureus Peptidoglycan-Induced Diarrhea
Am. J. Pathol., August 1, 2007; 171(2): 537 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
R. Kikkert, I. Bulder, E. R. de Groot, L. A. Aarden, and M. A. Finkelman
Potentiation of Toll-like receptor-induced cytokine production by (1->3)-{beta}-D-glucans: implications for the monocyte activation test
Innate Immunity, June 1, 2007; 13(3): 140 - 149.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
M. Nakao, T. Kajiya, Y. Sato, T. Somamoto, Y. Kato-Unoki, M. Matsushita, M. Nakata, T. Fujita, and T. Yano
Lectin Pathway of Bony Fish Complement: Identification of Two Homologs of the Mannose-Binding Lectin Associated with MASP2 in the Common Carp (Cyprinus carpio)
J. Immunol., October 15, 2006; 177(8): 5471 - 5479.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. M. Jawdat, G. Rowden, and J. S. Marshall
Mast Cells Have a Pivotal Role in TNF-Independent Lymph Node Hypertrophy and the Mobilization of Langerhans Cells in Response to Bacterial Peptidoglycan
J. Immunol., August 1, 2006; 177(3): 1755 - 1762.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. A. Fraser, S. S. Bohlson, N. Jasinskiene, N. Rawal, G. Palmarini, S. Ruiz, R. Rochford, and A. J. Tenner
C1q and MBL, components of the innate immune system, influence monocyte cytokine expression
J. Leukoc. Biol., July 1, 2006; 80(1): 107 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Innate ImmunityHome page
V. L. Runza, T. Hehlgans, B. Echtenacher, U. Zahringer, W. J. Schwaeble, and D. N. Mannel
Localization of the mouse defense lectin ficolin B in lysosomes of activated macrophages
Innate Immunity, April 1, 2006; 12(2): 120 - 126.
[Abstract] [PDF]

Home page
 Infect. Immun.Home page
A. Krarup, U. B. S. Sorensen, M. Matsushita, J. C. Jensenius, and S. Thiel
Effect of Capsulation of Opportunistic Pathogenic Bacteria on Binding of the Pattern Recognition Molecules Mannan-Binding Lectin, L-Ficolin, and H-Ficolin
Infect. Immun., February 1, 2005; 73(2): 1052 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Krarup, S. Thiel, A. Hansen, T. Fujita, and J. C. Jensenius
L-ficolin Is a Pattern Recognition Molecule Specific for Acetyl Groups
J. Biol. Chem., November 12, 2004; 279(46): 47513 - 47519.
[Abstract] [Full Text] [PDF]

This Article
Right arrow